Studying measurement variability in tumor volume and volume change on MDCT

点击翻译按钮获取中文摘要

DESCRIPTION (provided by applicant): For 30 years, the standard way to assess a patient's response to treatment has been to monitor changes in tumor diameter using serial CT exams. However, studies began to show the inadequacy of conventional methods in assessing tumor responses to novel targeted therapies. Indeed, our recent study correlating early radiographic response induced by a targeted therapy, gefitinib, with the presence of epidermal growth factor receptor mutations suggests that tumor volume change is better for detecting biologic activity of the target in non-small cell lung cancer. Despite the widespread use of CT in response assessment, contemporary analysis of CT data and its role in guiding clinical trial interpretation has neither been validated nor optimized. It is now critical that such a rigorous evaluation be undertaken as clinical trials begin incorporating volumetric CT (VCT) into the assessment of new therapies and as more computer algorithms haven been/are being developed for assisting in measuring tumor volumes. Our first goal is to systematically explore sources and variability in volume and volume change measurements that are introduced during image acquisition and tumor size measurement using both an FDA chest phantom with known ground truth (volume) and in vivo lung cancer tumors taken on same-day repeat CT scans (Aims 1 and 2). Achieving this goal will allow us to gain key insights into how and to what extent different CT vendor platforms and scanning parameters, serial CT scans, and image segmentation algorithms affect tumor volume measurement and subsequent response assessment. Such information will be essential for helping establish standards for CT imaging protocols and select appropriate algorithms to improve accuracy, consistency of volume measurements and response assessments in multicenter clinical trials. Even with improvements in accuracy and reproducibility, enhanced image quantification alone will not be accepted by the oncology community as an improved biomarker for novel therapies without showing a robust correlation of VCT with clinical outcomes. Our second goal, therefore, is to validate VCT as an early and more accurate biomarker for predicting pathologic response and disease free survival. We will do this in a prospective multicenter lung cancer trial (CALGB 30803) that is evaluating a novel neoadjuvant regimen (Aim 3). Because CT imaging technology is globally available, our algorithm can be widely distributed, run on standard computers and be integrated with picture archiving and communication systems, we expect that our findings will be broadly useful for both drug discovery and clinical care.